372
Participants
Start Date
September 17, 2021
Primary Completion Date
September 27, 2022
Study Completion Date
October 14, 2022
FMX101
topically once daily
China-Japan Friendship Hospital, Beijin
Beijing Friendship Hospital, Capital Medical University, Beijing
Xuanwu Hospital Capital Medical University, Beijing
Peking University Shougang Hospital, Beijing
Peking University Third Hospital, Beijing
Beijing Tsinghua Changgung Hospital, Beijin
The First Hosptial of China Medical University, Shenyang
Shengjin Hospital of China Medical University, Shenyang
The First Bethune Hosptial of Jilin University, Changchun
Shanghai Medical College of Fudan University, Shanghai
Shanghai Skin Disease Hospital Skin Disease Hospital of Tongji University, Shanghai
Institute of Dermatology Chinese Academy of Medical Sciences, Nanjin
Wuxi People's Hospital, Wuxi
Qilu Hospital of Shandong University, Jinan
The Affiliated Hosptial of Qingdao University, Qingdao
Tianjin Medical University General Hospital, Tianjin
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjing
Hangzhou Third People's Hospital, Hangzhou
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou
The Southwest Hospital Of Amu, Chongqing
The First Affiliated Hospital Of Chongqing Medical University, Chongqing
The Third Xiangya Hospital Of Central South University, Changsha
Dermatology Hosptial of Southern Medical University, Yuexiu
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
West China Hospital Sichuan University, Chengdu
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
The Second Hospital Of Hebei Medical University, Shijiazhuang
The Second Affiliated Hosptial Zhejiang University School Of Medicine, Hangzhou
Cutia Therapeutics (Shanghai) Co., Ltd
INDUSTRY